ArticleJournal of hypertension2018
Renal sympathetic denervation in Sweden: a report from the Swedish registry for renal denervation.
Article in Journal of hypertension, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV-Risk Study.Journal of clinical hypertension (Greenwich, Conn.) · 2021Trial
- Article
- Clinical event reductions in high-risk patients after renal denervation projected from the global SYMPLICITY registry.European heart journal. Quality of care & clinical outcomes · 2023Article
- Celiac ganglia neurolysis suppresses high blood pressure in rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements.Frontiers in cardiovascular medicine · 2023Article
- Renal denervation in the antihypertensive arsenal - knowns and known unknowns.Journal of hypertension · 2022Article
- Device-based therapies for arterial hypertension.Nature reviews. Cardiology · 2020Review
- Clinical benefits and safety of renal denervation in severe arterial hypertension: A long-term follow-up study.Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
- New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension.International Journal of Cardiology. Hypertension · 2019Review
- Selective renal denervation guided by renal nerve stimulation: mapping renal nerves for unmet clinical needs.Journal of human hypertension · 2019Article
- Joint UK societies' 2019 consensus statement on renal denervation.Heart (British Cardiac Society) · 2019Article
- 2019 Consensus Statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on Renal Denervation for the Management of Arterial Hypertension.Acta Cardiologica Sinica · 2019Review
- Renal Denervation in High-risk Patients with Hypertension.Heart international · 2019Review
- Predictors for success in renal denervation-a single centre retrospective analysis.Scientific reports · 2018Article
- Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- Catheter-based renal denervation in hypertension: heading for new shores.Journal of hypertension · 2018Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on byReply.2019
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry. PURPOSE: To assess the safety and efficacy of RDN on patients with resistant hypertension in a real-world clinical setting.
methodsThis nationwide database contains patient characteristics, procedural details, and follow-up data on all RDN procedures performed in Sweden. Consecutive procedures between 2011 and 2015 were included.
resultsThe data analysis consists of 252 patients (mean age 61 ± 10 years, 38% women; mean 4.5 ± 1.5 antihypertensive drugs). Office SBP and DBP and 24-h ambulatory blood pressure (BP) decreased 6 months after RDN (176 ± 23/97 ± 17 to 161 ± 26/91 ± 16 mmHg, both P < 0.001; and 155 ± 17/89 ± 14 to 147 ± 18/82 ± 12 mmHg, both P < 0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up.
conclusionIn this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension. The procedure proved to be feasible and associated with a low-complication rate, including long-term adverse events.
Indexed as
Identifiers
29210862What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.